Flow Cytometric Monitoring of Drug Resistance in Human Solid Tumors
Resistance to cancer chemotherapy continues to be a major hurdle in successful management of refractory human malignancies. Drug resistance may be intrinsic or acquired after chemotherapy. Several well-known extracellular factors such as drug metabolism and pharmacokinetics may be responsible for failure of chemotherapy. However, a major reason for drug resistance resides at the cellular level and often involves cellular mechanisms which under normal conditions may have other protective and important biological roles. Tumor cell resistance is believed to be multifactorial involving altered drug transport (influx, retention and efflux), and biochemical mechanisms such as xenobiotic detoxification/ alternate metabolic pathways, and altered targets (1–3). Multiple drug resistance (MDR) has been recently described as a phenomenon in which tumor cells are resistant to a variety of unrelated natural products such as alkaloids and antibiotics used as cancer chemotherapeutic agents (1,3).
KeywordsMultiple Drug Resistance Drug Retention Flow Cytometric Study Cellular Retention MDRl Gene
Unable to display preview. Download preview PDF.
- 3.Kessel D (ed): Resistance to antineoplastic drugs. CRC Press Inc., Boca Raton, 1989.Google Scholar
- 14.Tsuro T: Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat. Rep. 67:889–894, 1986.Google Scholar
- 19.Preisler H: Alteration of binding of the supravital dye Hoechst 3 3342 of human leukemic cells by adriamycin. Cancer Treat. Rep. 62:1393–1396, 1978.Google Scholar
- 22.Sridhar KS, Krishan A, Samy TSA, et al: Prochlorperazine as a doxorubucin-efflux blocker: Phase I clinical and pharmacokinetics studies. Cancer Chemother. Pharmacol. 31:423–430.Google Scholar
- 27.Jakoby W, Habig W: In: Enzymatic basis of detoxification, W Jakoby (ed), Academic Press, NY, 2:63–94, 1980.Google Scholar
- 31.Russo A, Mitchell JB: Potentiation and protection of doxorubucin cytotoxicity by cellular glutathione modulation. Cancer Treat. Rep. 69:12 93–1296, 1985.Google Scholar